Psyomics announces Stephanie Martlew as new CEO

October 7, 2021

Psyomics, a Cambridge University spin-out developing technology to support earlier and improved mental health diagnosis and treatment management, have appointed a new CEO, effective 1st October 2021

Psyomics, a Cambridge University spin-out, developing technology to support earlier and improved mental health diagnosis and treatment management, has appointed a new CEO, effective 1st October 2021.

Stephanie Martlew brings with her over 10 years of experience driving growth in creating scalable ways to improve mental health outcomes by using evidence-based digital technology.

Psyomics announced this week that they have strengthened their executive board with the appointment of accomplished digital mental health leader, Stephanie Martlew (née Ruskin).

Martlew joins Psyomics to help align the company to strong potential market areas, facilitating its strategic shift from research to commercialisation.

She brings a wealth of specialist knowledge in commercialising transformative mental health products as well as scaling health technology start-ups across international markets. She has previously held leadership positions within two notable UK based mental health technology companies, supporting both from early-stage start-ups to fast-growing scale-up.

Martlew said: “Psyomics’ product, Censeo, is novel and has potential to bring great value to the mental health industry. I am convinced that Censeo will be able to benefit both those looking to improve their mental health and the hugely stretched service providers who do their best every day to provide high-quality care. Having spoken to the team and investors, I am confident that the technology, timing and culture is there to make a tremendous impact.”

“We are delighted to have Stephanie join us. Her proven experience in this industry and leadership ability make her a great fit for the company,” said Kevin McDonnell, Chair. “Stephanie has spent her career so far establishing commercially viable digital mental health companies, and we look forward to her contributions to Psyomics’ ongoing success.”

While at virtual reality technology start-up Oxford VR, Stephanie managed global operational and commercial activity at Director level. Her success includes developing and mobilising a series of large-scale commercial contracts across the UK, US, Asia and Europe.

As one of the founding members of Ieso Digital Health (formerly PsychologyOnline), Stephanie helped the company expand across the NHS, before developing further growth areas outside of the UK which included replicating the business in the US.  Stephanie launched the online CBT (cognitive behavioural therapy) service’s first commercial UK contracts with NHS adult and child mental health commissioners and providers. She also managed the clinical operations, including the development and implementation of a highly sophisticated learning and development platform for clinicians that greatly strengthened the company’s value proposition.

“Stephanie shares the core values and beliefs that are integral to Psyomics’ vision. We want to ensure easy and early access to a mental health assessment and support for everyone. It is time that mental health emerges from the shadows and receives the same recognition as other common health concerns in terms of diagnosis, treatment and especially prevention”, comments Sabine Bahn, co-founder and chief medical officer. “Steph’s understanding and passion for the importance of clinical excellence and scientific validity alongside fast-paced technological innovation make her an excellent cultural fit for Psyomics. She has proven experience of fostering collaborations and motivating teams to reach their full potential.”

Barnaby Perks, non-executive director, comments, “Stephanie is a born leader who knows how to align cross-functional teams to generate commercial and clinical impact. Her rich experience in deploying mental health technologies with global healthcare providers makes her a perfect fit for Psyomics as we transition from a research focus to commercialisation.”

Other news stories